Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014', provides an overview of the Hematopoietic Stem Cell Transplantation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hematopoietic Stem Cell Transplantation Overview 8 Therapeutics Development 9 Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview 9 Pipeline Products for Hematopoietic Stem Cell Transplantation - Comparative Analysis 10 Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies 11 Hematopoietic Stem Cell Transplantation - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Hematopoietic Stem Cell Transplantation - Products under Development by Companies 16 Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development 17 Actinium Pharmaceuticals, Inc. 17 Athersys, Inc. 18 BioLineRx, Ltd. 19 Celldex Therapeutics, Inc. 20 Cellerant Therapeutics, Inc. 21 Hospira, Inc. 22 Kiadis Pharma B.V. 23 MediPost Co., Ltd. 24 Novartis AG 25 Pharmalink AB 26 Polyphor Ltd. 27 Recoly N.V. 28 TaiGen Biotechnology Co., Ltd. 29 Targazyme, Inc. 30 TikoMed AB 31 Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 Actimab-B - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ATIR - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BL-8040 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 burixafor - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 busulfan liposomal IR - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CDX-301 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CordSafe - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 filgrastim - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 HSC-835 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Iomab-B - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 MultiStem - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 NecLip-G-CSF - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 POL-5551 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 POL-6326 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Promostem - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 romyelocel-L - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 TM-400 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 TXA-127 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 TZ-101 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates 71 Hematopoietic Stem Cell Transplantation - Dormant Projects 90 Hematopoietic Stem Cell Transplantation - Discontinued Products 91 Hematopoietic Stem Cell Transplantation - Product Development Milestones 92 Featured News & Press Releases 92 Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation 92 Sep 03, 2014: BioLineRx Doses First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment 93 Jun 08, 2014: ScinoPharm to Provide Active Pharmaceutical Ingredient to F*TaiGen for Novel Stem Cell Drug 94 Jan 29, 2014: Actinium Engages Goodwin Biotechnology to Supply Iomab-B for Its Phase 3 Clinical Study 94 Dec 19, 2013: Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab-B 95 Dec 18, 2013: Targazyme Reports Interim Phase I/IIa Trial Results for TZ101 96 Dec 10, 2013: Celldex's CDX-301 in Combination with Mozobil Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013 97 Oct 03, 2013: Actinium Pharmaceuticals Announces Upcoming Webinar To Discuss Iomab-B 98 Sep 11, 2013: Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR and Study Meets Primary Objective 98 Jul 09, 2013: MultiStem Cell Therapy May Overcome Major Challenges in Organ Transplantations 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 102 Disclaimer 10
List of Tables Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2014 9 Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 17 Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2014 18 Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H2 2014 19 Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2014 20 Hematopoietic Stem Cell Transplantation - Pipeline by Cellerant Therapeutics, Inc., H2 2014 21 Hematopoietic Stem Cell Transplantation - Pipeline by Hospira, Inc., H2 2014 22 Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma B.V., H2 2014 23 Hematopoietic Stem Cell Transplantation - Pipeline by MediPost Co., Ltd., H2 2014 24 Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2014 25 Hematopoietic Stem Cell Transplantation - Pipeline by Pharmalink AB, H2 2014 26 Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H2 2014 27 Hematopoietic Stem Cell Transplantation - Pipeline by Recoly N.V., H2 2014 28 Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 29 Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2014 30 Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H2 2014 31 Assessment by Monotherapy Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 34 Number of Products by Stage and Mechanism of Action, H2 2014 36 Number of Products by Stage and Route of Administration, H2 2014 38 Number of Products by Stage and Molecule Type, H2 2014 40 Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 71 Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2014 90 Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2014 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
